How can we help?
How will the new reimbursement chapter and companioning legislative amendments about personalized medicines and their markers affect the reimbursement of our product?
Does our health economic model meet the methodological Belgian recommendations? and how to implement our health economic model in the Belgian context?
How can the new legislation be translated to a pragmatic approach?
What is the optimal path for reimbursement?
How to write the pricing & reimbursement dossier? We need support with submission of our pricing & reimbursement dossier in Belgium.
Is there an opportunity for an early access program to medicines in Belgium?
What are the key factors determining the reimbursement for our drug in Belgium?
We need help with our systematic literature review
Why do we need to pay certain taxes for our product to the Belgian government (NIHDI/FAMHP)?
How will our pricing & reimbursement application be interpreted by the NIHDI/RIZIV?
What are the most important rules to know about the complex market access legal system in Belgium?
How can we optimize the structure of our pricing & reimbursement dossier?
What are the key factors determining the reimbursement for our medical device in Belgium?
Will our product end up in the same added value class after the legislative amendments for pricing & reimbursement in Belgium?
What managed entry agreement (MEA)/ price could be negotiated for our drug/medical device in Belgium?
How to create a budget impact analysis to support our Belgian Price and reimbursement dossier? How to collect Belgian data for this budget impact analysis?
Is our health economic model in line with the Belgian recommendations?
How can we get access for our products in Luxembourg?
How do we collect the missing data for our Belgian reimbursement dossier?
Go to home
Scroll to top